Clik here to view.
It takes a village : What Ranbaxy’s Synriam tells us
Pic sourced from mmv.org Synriam, Ranbaxy’s new anti-malarial drug combination, is the first new drug R&D project by an Indian generics company that’s yielded a marketable drug. That’s big in...
View ArticleClik here to view.
Cipla hires former Teva/GSK honcho to head global respiratory
Mumbai-based generic drugs producer Cipla has recruited Frank Pieters a former senior vice-president at global generics leader Teva of Israel to head its European business, said two persons familiar...
View ArticleClik here to view.
India drags its feet on a marketing code for drug companies
Online and offline media have extensively covered the $3bn fine levied by the US government on UK’s GlaxoSmithKline for illegal and unethical marketing of a clutch of brands. See here. Back in India,...
View ArticleClik here to view.
FDI in pharma : India’s quick fix
India seems set to reverse a ten year-old policy governing foreign direct investment (FDI) in pharmaceuticals. If Prime Minister Manmohan Singh gives his nod to the recommendations of an...
View ArticleClik here to view.
FDI in pharma : another punch
The issue of controlling foreign direct investment (FDI) in the Indian pharmaceutical sector continues to make headlines with various arms of the government putting forth their own formulas to tame the...
View ArticleClik here to view.
White knight : Takeda advance gives Advinus reprieve
Japanese drug maker Takeda has come to the rescue of the beleaguered Advinus Therapeutics, a Tata group company, according to two persons familiar with the development. Takeda has advanced in the...
View ArticleClik here to view.
India’s move to vanilla generics : Don’t hold your breath
By now, the news that India wants to move away from branded generics and encourage vanilla generics to bring down drug prices has gone around the world. But all those who think a structural reform of...
View ArticleClik here to view.
India’s new drug pricing policy : will data be the stumbling block?
On December 7, India’s National Pharmaceutical Pricing Policy 2012 was finally tabled in Parliament. Assuming that this policy does get rolled out irrespective of a Supreme Court hearing on drug...
View ArticleClik here to view.
India and drug safety : Latest PVig attempt showing promise
India seems to be making slow but sure progress towards reversing its abysmal track record in pharmacovigilance – medical jargon for monitoring the safety of marketed medicines. The country has...
View ArticleClik here to view.
Guest column : Indian patent rulings and pharma strategies
The Indian government made several critical patent decisions over the past year. Their impact on the Indian intellectual property (IP) landscape is still evolving, with important implications for IP...
View ArticleClik here to view.
The Ranbaxy effect : My op-ed in The Indian Express
This morning’s Indian Express op-ed page carries my views on the impact of the Ranbaxy revelations on Indian generics. To read click here. Just to clarify, I had attributed numbers on US imports of...
View ArticleClik here to view.
Guest column : Is Indian Pharma’s spectacular growth Bonanza or Bubble?
Indian pharmaceutical companies’ profits have grown hugely in recent years. Contrary to claims that India’s robust generics industry is driven by being ‘the drug store for the developing world’,...
View ArticleClik here to view.
Guest column : Ponzi schemes in Indian pharma sales a real problem
Last week, a PharmaAsia News story reported sales malpractices at Mumbai-based drug maker Novartis India. The article, which told of how representatives for Novartis’ market-leading diabetes treatment...
View ArticleClik here to view.
Guest column : Can Indian generics move from blockbusters to biologics?
For generic dug manufacturers in India and elsewhere the number of blockbuster drugs that have recently come off patent has been a bonanza. But the product mix coming off patent over the next three...
View ArticleClik here to view.
Guest column : In defence of India’s pioglitazone ban
There is some debate on whether the Indian regulatory agency ought to have banned anti-diabetes drug pioglitazone given the large diabetic population in India. The decision to ban is a correct and...
View ArticleClik here to view.
Guest column : Indian Pharma and collaborating beyond the obvious
Last month, Pfizer Asia Pacific, Glaxo Wellcome Manufacturing and Siemens signed on as founding members of a consortium that will offer a platform to pharma companies to address challenges such as...
View ArticleClik here to view.
Mitigating regulatory risk at Indian Pharma
Earlier this month, Mumbai-based brokerage Ambit Capital published an Expert White Paper on pharmaceuticals in which it observed that the US Food & Drug Administration’s decision to conduct...
View ArticleClik here to view.
Can Indian regulator “fix” drug combos?
Come September 30, a new deadline that the Indian drugs regulator, Drugs Controller General of India, has set for state food and drug administrations to produce safety and efficacy data on scores of...
View ArticleClik here to view.
India & drug pricing : Now, list of essential meds questioned
In continuation of the challenges arising from the roll-out of India’s new drug pricing policy, a question has now been raised on the current National List of Essential Medicines (NLEM) that specifies...
View ArticleClik here to view.
Stop tinkering with FDI norms : my column in the Indian Express
Today’s edition of the Indian Express has an edit piece that I have authored on why the government should stop repeatedly tinkering with India’s foreign direct investment (FDI) policy for...
View Article
